Oncology Drugs Market - North America, Europe, EMEA, APAC : US, Canada, China, Germany, UK - Forecast 2023-2027
| Published: Oct 2023 | Pages: 155 | SKU: IRTNTR75604 |
Oncology Drugs Market Size 2023-2027
The Oncology Drugs Market size is estimated to increase by USD 151.84 billion and grow at a CAGR of 11.99% between 2023 and 2027. Market expansion relies on multiple factors, including the escalating global incidence of cancer, the imperative for cost reduction in drug discovery and development, and the increasing efforts by governments and non-profit entities to raise awareness about cancer prevention. Challenges encompass the exorbitant expenses of cancer treatment medications, the adverse effects linked to chemotherapy, and the rigorous regulatory measures governing oncology drugs. Overcoming these obstacles necessitates innovative approaches to reduce the cost burden of cancer therapies, mitigate the adverse impacts of treatment, and navigate regulatory frameworks effectively. By addressing these challenges adeptly, the market can leverage its growth drivers and establish a resilient position in providing effective cancer treatment solutions, contributing to improved patient outcomes and enhanced public health worldwide.
What will be the size of the Oncology Drugs Market During the Forecast Period?
To learn more about this report, Request Free Sample
Market Segments
This market report extensively covers market segmentation by therapy (targeted therapy, immunotherapy, hormonal therapy, and chemotherapy), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
The market share growth by the targeted therapy segment will be significant during the forecast period. Targeted therapy is a form of chemotherapy (drug therapy), a type of precision cancer treatment. Targeted therapy drugs are directed to specific features in cancer cells, unlike traditional or standard chemotherapy which targets a variety of fast-growing cells across the entire human body irrespective of whether they're cancerous or not.
Get a glance at the market contribution of various segments View the PDF Sample
The targeted therapy segment shows a gradual increase in the market share of 68.17 billion in 2017 and continue to grow by 2021. Targeted therapy drugs interfere with specific molecules found in receptors or proteins that are found on and inside cancer cells. Targeted therapy targets or inhibits the genetic characteristics of cells regulating growth and differentiation with a view to stopping or slowing tumour development.
Key Regions
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global oncology cancer drugs market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America is a dominant region in the global market, with the US and Canada being the leading revenue-generating countries. In view of the increasing use of minimally invasive surgery, the North American market for cancer drugs is expected to grow at a significant rate during the forecast period. The growing prevalence of cancer in the region is also expected to fuel the demand.
Market Dynamics and Customer Landscape
The market for Oncology drugs operates within a complex ecosystem involving B2B, B2G, and B2C transactions, driving drug revenues and impacting financial information. Money and VAT considerations shape decisions, guided by specific rationale and influenced by industry associations. Cutting-edge treatments like Pluvicto from the Aichi Cancer Center and innovations in Artificial Intelligence by Orserdu are transforming cancer care. From addressing ER+ and ESR1-mutated breast cancer with AstraZeneca’s Faslodex injection to Chemoprevention and Immunotherapy, the focus remains on combating Cancer through diverse modalities like Surgery, Radiotherapy, Chemotherapy, Targeted therapy, and Hormone therapy. These advancements, bolstered by ongoing Clinical trials, promise a brighter future in the fight against cancer.
Key Market Driver
The increasing prevalence of cancer globally is notably driving market growth. Cancer is one of the leading causes of death worldwide. Lung, liver, stomach, colorectal, breast, and esophageal cancers are commonly prevalent among the population worldwide. The incidence of melanoma, prostate, and lung cancers is expected to increase significantly.
Moreover, changes in lifestyle, unhealthy diets, smoking, fewer pregnancies, and longtime exposure to UV rays are expected to increase the prevalence of cancers, such as breast cancer, lung cancer, and colorectal cancer, which are associated with these risk factors. Such factors are expected to increase the demand, which will fuel the growth of the market in focus during the forecast period.
Significant Market Trends
The rising adoption of immunotherapy is a primary trend in the market. Immunotherapy is a promising and fast-growing cancer treatment that involves stimulating the immune system of the patient. Immunotherapy has been demonstrated to be very effective for patients who are in the third or fourth stages of the disease. However, immunotherapy is not recommended for all patients. Depending on the patient's state of health and type of tumor, this is different. A wide variety of diseases can be treated with immunotherapeutic agents such as lung, kidney, bladder, melanoma, neck, and lymphoma.
A study conducted in India revealed that an extremely low dose of the immunotherapy drug nivolumab (Opdivo) extended the lives of patients with advanced head and neck cancer. New technologies are being developed to enhance the diagnosis, treatment, and management of cancer patients in countries like India, where the incidence of cancer is increasing. This will be a key factor in driving the growth of the oncology cancer drugs market over the forecast period.
Major Market Challenge
The high cost of cancer treatment drugs is a major challenge. Cancer is one of the leading causes of death worldwide, with millions of people suffering from different forms of the disease each year. The cost of chemotherapy varies widely depending on several factors, e.g. type of cancer, degree of illness, treatment plan, and country in which the patient is resident. These costs can be prohibitive for many patients, especially those without health insurance or with limited financial resources. This high cost has led to criticisms from patients, healthcare providers, and government officials.
Moreover, The high cost of cancer treatment drugs can have serious consequences for patients. These drugs may be difficult to afford for many patients, leading to a delay or interruption of treatment. Patients can refuse to take any medicine at all, risking their health and life. Additionally, the high cost of cancer treatment drugs can strain healthcare systems and lead to higher overall healthcare costs. Consequently, the growth of the global oncology cancer drugs market is considered to be somewhat hampered by such factors during the forecast period.
Key Market Customer Landscape
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Who are the Major Oncology Drugs Market Players?
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the oncology cancer drugs market.
AbbVie Inc. - The company offers oncology drugs such as IMBRUVICA.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
- Amgen Inc.
- Apikos Pharma
- Arlak Biotech Pvt. Ltd.
- Aspen Pharmacare Holdings Ltd
- Astellas Pharma Inc.
- AstraZeneca
- Athenex Inc.
- Bayer AG
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Kremedine Health Pvt Ltd.
- Merck and Co. Inc.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Segment Overview
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
- Therapy Outlook
- Targeted therapy
- Immunotherapy and hormonal therapy
- Chemotherapy
- Distribution Channel Outlook
- Offline
- Online
- Region Outlook
- North America
- The U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- ROW
- Australia
- Argentina
- Rest of the World
- North America
Market Analyst Overview
The market is driven by various factors, such as increasing healthcare expenditure and the emergence of new drugs due to expiring patents. B2B, B2G, and B2C transactions play a pivotal role in drug revenues, with financial information and VAT considerations shaping decisions. Advanced statistical methods aid in analyzing industry trends and prescription drugs demand. Leading pharmaceutical companies like Pluvicto and AstraZeneca are developing innovative treatments for cancers like ER+ and ESR1-mutated breast cancer. Additionally, Artificial Intelligence is revolutionizing clinical trials and drug discovery. The market caters to various cancer indications, including stomach, prostate, and liver cancer, with reimbursement policies influencing access to treatments through different channels like hospital, retail, and online pharmacies. Money is a key consideration in the development of AstraZeneca’s Faslodex injection, guided by a specific rationale to combat prostate cancer. Its availability through hospital pharmacies underscores its importance among anticancer drugs in the drug class type targeting this indication.
The market is shaped by various factors, including financial considerations and specific rationales behind drug development. Industry associations and historical developments provide insights into market trends. Pharmaceutical companies continually enhance their pipeline to address diverse cancer types like stomach cancer, esophagus cancer, cervical cancer, kidney cancer, and bladder cancer. Exchange rates influence the accessibility of drugs worldwide, impacting collaborations such as those with renowned institutions like the Aichi Cancer Center and Orserdu. Notable treatments like AstraZeneca’s Faslodex and Fulvestrant Injection contribute to advanced chemoprevention and hormone therapy. These innovations are pivotal in augmenting the efficacy of radiotherapy and combating the challenges posed by various cancer indications, ensuring patients receive optimal care through both hospital and retail pharmacies.
|
Oncology Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
155 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 11.99% |
|
Market growth 2023-2027 |
USD 151.84 billion |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
10.77 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 44% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., Apikos Pharma, Arlak Biotech Pvt. Ltd., Aspen Pharmacare Holdings Ltd, Astellas Pharma Inc., AstraZeneca, Athenex Inc., Bayer AG, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Kremedine Health Pvt Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Bristol Myers Squibb Co. |
|
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our Market forecast report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
- Precise estimation of the size of the market size and its contribution to the parent market
- Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
- Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
- Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global oncology drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global oncology drugs market 2017 - 2021 ($ billion)
- 4.2 Therapy Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ billion)
- 4.3 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ billion)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Therapy
- 6.1 Market segments
- Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
- 6.2 Comparison by Therapy
- Exhibit 32: Chart on Comparison by Therapy
- Exhibit 33: Data Table on Comparison by Therapy
- 6.3 Targeted therapy - Market size and forecast 2022-2027
- Exhibit 34: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)
- 6.4 Immunotherapy and hormonal therapy - Market size and forecast 2022-2027
- Exhibit 38: Chart on Immunotherapy and hormonal therapy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on Immunotherapy and hormonal therapy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on Immunotherapy and hormonal therapy - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Immunotherapy and hormonal therapy - Year-over-year growth 2022-2027 (%)
- 6.5 Chemotherapy - Market size and forecast 2022-2027
- Exhibit 42: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
- 6.6 Market opportunity by Therapy
- Exhibit 46: Market opportunity by Therapy ($ billion)
- Exhibit 47: Data Table on Market opportunity by Therapy ($ billion)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 48: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 49: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 50: Chart on Comparison by Distribution Channel
- Exhibit 51: Data Table on Comparison by Distribution Channel
- 7.3 Offline - Market size and forecast 2022-2027
- Exhibit 52: Chart on Offline - Market size and forecast 2022-2027 ($ billion)
- Exhibit 53: Data Table on Offline - Market size and forecast 2022-2027 ($ billion)
- Exhibit 54: Chart on Offline - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Offline - Year-over-year growth 2022-2027 (%)
- 7.4 Online - Market size and forecast 2022-2027
- Exhibit 56: Chart on Online - Market size and forecast 2022-2027 ($ billion)
- Exhibit 57: Data Table on Online - Market size and forecast 2022-2027 ($ billion)
- Exhibit 58: Chart on Online - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Online - Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ billion)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ billion)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2022-2027 (%)
- Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 China - Market size and forecast 2022-2027
- Exhibit 87: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 88: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 89: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.9 Japan - Market size and forecast 2022-2027
- Exhibit 91: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
- Exhibit 92: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
- Exhibit 93: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Japan - Year-over-year growth 2022-2027 (%)
- 9.10 Germany - Market size and forecast 2022-2027
- Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.11 UK - Market size and forecast 2022-2027
- Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ billion)
- Exhibit 104: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 108: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 109: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 111: AbbVie Inc. - Overview
- Exhibit 112: AbbVie Inc. - Product / Service
- Exhibit 113: AbbVie Inc. - Key news
- Exhibit 114: AbbVie Inc. - Key offerings
- 12.4 Amgen Inc.
- Exhibit 115: Amgen Inc. - Overview
- Exhibit 116: Amgen Inc. - Product / Service
- Exhibit 117: Amgen Inc. - Key offerings
- 12.5 Aspen Pharmacare Holdings Ltd
- Exhibit 118: Aspen Pharmacare Holdings Ltd - Overview
- Exhibit 119: Aspen Pharmacare Holdings Ltd - Business segments
- Exhibit 120: Aspen Pharmacare Holdings Ltd - Key offerings
- Exhibit 121: Aspen Pharmacare Holdings Ltd - Segment focus
- 12.6 AstraZeneca
- Exhibit 122: AstraZeneca - Overview
- Exhibit 123: AstraZeneca - Product / Service
- Exhibit 124: AstraZeneca - Key news
- Exhibit 125: AstraZeneca - Key offerings
- 12.7 Athenex Inc.
- Exhibit 126: Athenex Inc. - Overview
- Exhibit 127: Athenex Inc. - Product / Service
- Exhibit 128: Athenex Inc. - Key offerings
- 12.8 Bayer AG
- Exhibit 129: Bayer AG - Overview
- Exhibit 130: Bayer AG - Business segments
- Exhibit 131: Bayer AG - Key news
- Exhibit 132: Bayer AG - Key offerings
- Exhibit 133: Bayer AG - Segment focus
- 12.9 Bristol Myers Squibb Co.
- Exhibit 134: Bristol Myers Squibb Co. - Overview
- Exhibit 135: Bristol Myers Squibb Co. - Product / Service
- Exhibit 136: Bristol Myers Squibb Co. - Key news
- Exhibit 137: Bristol Myers Squibb Co. - Key offerings
- 12.10 Eli Lilly and Co.
- Exhibit 138: Eli Lilly and Co. - Overview
- Exhibit 139: Eli Lilly and Co. - Product / Service
- Exhibit 140: Eli Lilly and Co. - Key news
- Exhibit 141: Eli Lilly and Co. - Key offerings
- 12.11 F. Hoffmann La Roche Ltd.
- Exhibit 142: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 143: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 144: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 145: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 146: F. Hoffmann La Roche Ltd. - Segment focus
- 12.12 GlaxoSmithKline Plc
- Exhibit 147: GlaxoSmithKline Plc - Overview
- Exhibit 148: GlaxoSmithKline Plc - Business segments
- Exhibit 149: GlaxoSmithKline Plc - Key news
- Exhibit 150: GlaxoSmithKline Plc - Key offerings
- Exhibit 151: GlaxoSmithKline Plc - Segment focus
- 12.13 Johnson and Johnson Services Inc.
- Exhibit 152: Johnson and Johnson Services Inc. - Overview
- Exhibit 153: Johnson and Johnson Services Inc. - Business segments
- Exhibit 154: Johnson and Johnson Services Inc. - Key news
- Exhibit 155: Johnson and Johnson Services Inc. - Key offerings
- Exhibit 156: Johnson and Johnson Services Inc. - Segment focus
- 12.14 Novartis AG
- Exhibit 157: Novartis AG - Overview
- Exhibit 158: Novartis AG - Business segments
- Exhibit 159: Novartis AG - Key offerings
- Exhibit 160: Novartis AG - Segment focus
- 12.15 Pfizer Inc.
- Exhibit 161: Pfizer Inc. - Overview
- Exhibit 162: Pfizer Inc. - Product / Service
- Exhibit 163: Pfizer Inc. - Key news
- Exhibit 164: Pfizer Inc. - Key offerings
- 12.16 Sanofi
- Exhibit 165: Sanofi - Overview
- Exhibit 166: Sanofi - Business segments
- Exhibit 167: Sanofi - Key news
- Exhibit 168: Sanofi - Key offerings
- Exhibit 169: Sanofi - Segment focus
- 12.17 Takeda Pharmaceutical Co. Ltd.
- Exhibit 170: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 171: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 174: Inclusions checklist
- Exhibit 175: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 176: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 177: Research methodology
- Exhibit 178: Validation techniques employed for market sizing
- Exhibit 179: Information sources
- 13.5 List of abbreviations
- Exhibit 180: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
oncology drugs market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis